

FDA-AE-T07**Deaths****Safety Population**

Deaths	Xanomeline Low Dose (N=XX) n (%)	Xanomeline High Dose (N=XX) n (%)	Placebo (N=XX) n (%)
Total deaths	XX (XX.X)	XX (XX.X)	XX (XX.X)
Cause of death {alphabetical order}	XX (XX.X)	XX (XX.X)	XX (XX.X)
Treatment-emergent deaths [1]	XX (XX.X)	XX (XX.X)	XX (XX.X)
Cause of death {alphabetical order}	XX (XX.X)	XX (XX.X)	XX (XX.X)
Non treatment-emergent deaths [2]	XX (XX.X)	XX (XX.X)	XX (XX.X)
Cause of death {alphabetical order}	XX (XX.X)	XX (XX.X)	XX (XX.X)

Source: ADSL; Program name: fda-ae-t07.sas;

Abbreviations: N, number of subjects in treatment arm; n, number of subjects with adverse event

[1] Treatment-emergent death is defined as death with onset after the first dose of study drug.

[2] Non treatment-emergent death is defined as death that occurred beyond the protocol-defined treatment-emergent adverse event period.

Programming Notes: For "Cause of death" use MedDRA preferred term and list them in an alphabetical order.